AMENDMENT NO. 2 TO SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • August 3rd, 2017 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
This Amendment No. 2 to Sponsored Research Agreement (this “Amendment No. 2”) is entered into and made effective as of March 31, 2017 (the “Amendment No. 2 Effective Date”) by and between Juno Therapeutics, Inc., (“Sponsor”), a Delaware corporation, and Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (“Institute”), a Washington nonprofit corporation.
AMENDMENT NO. 3 TO SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • August 3rd, 2017 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Sponsored Research Agreement (this “Amendment No. 3”) is entered into and made effective as of May 2, 2017 (the “Amendment No. 3 Effective Date”) by and between Juno Therapeutics, Inc., (“Sponsor”), a Delaware corporation, and Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (“Institute”), a Washington nonprofit corporation.
